KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Investing Activities (2018 - 2024)

Esperion Therapeutics' Cash from Investing Activities history spans 7 years, with the latest figure at -$167000.0 for Q3 2024.

  • For Q3 2024, Cash from Investing Activities changed N/A year-over-year to -$167000.0; the TTM value through Jun 2025 reached -$167000.0, down 11.33%, while the annual FY2024 figure was -$317000.0, 100.75% down from the prior year.
  • Cash from Investing Activities reached -$167000.0 in Q3 2024 per ESPR's latest filing, down from -$77000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $33.0 million in Q3 2022 to a low of -$50.5 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is $1.5 million, with a median of $1.1 million recorded in 2020.
  • Peak YoY movement for Cash from Investing Activities: tumbled 341.98% in 2020, then surged 250.0% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$12.7 million in 2020, then tumbled by 298.26% to -$50.5 million in 2021, then skyrocketed by 76.64% to -$11.8 million in 2022, then surged by 248.38% to $17.5 million in 2023, then tumbled by 100.95% to -$167000.0 in 2024.
  • Per Business Quant, the three most recent readings for ESPR's Cash from Investing Activities are -$167000.0 (Q3 2024), -$77000.0 (Q2 2024), and -$73000.0 (Q1 2024).